Utilisation des modulateurs de la voie de la thrombine et de la protéine C dans les CIVD : résultats des essais cliniques

Abstract

A correlation between acquired antithrombin (AT) and protein C (PC) deficiencies, multiple organ dysfunction and mortality has been demonstrated in various clinical conditions. In addition, the evolution of these deficiencies over time seems to have a more pronounced predictive value. Thrombin and PC pathways modulation in DIC has been evaluated in various clinical trials. This chapter aims at reviewing the clinical situations associated with DIC and in which the effects of these therapies have been evaluated. Congenital PC deficiency and heparin resistance are not considered here. AT and PC therapies are reviewed with regard to their influence on DIC, multiple organ dysfunction and mortality. AT supplementation improves DIC biomarkers and in some situations, organ dysfunction scores. Its effect on mortality remains to be demonstrated. PC concentrates seem to favourably improve coagulation disorders observed in DIC. However, no controlled study has evaluated its effect on mortality. Activated protein C has been demonstrated to improve survival in patients with severe sepsis at increased risk of death and DIC biomarkers but is associated with an increased risk of bleeding. Finally, heparin improves coagulation parameters observed in DIC but has not been demonstrated to improve survival. Its influence on the effects of other DIC therapies has to be evaluated.